Reduced animal testing could unlock host of benefits, but not overnight

FDA’s plan to move away from animal tox testing is not new — it’s been decades in the making — but the moment might be right for accelerating progress. 

If done carefully, replacing animal models with human- or AI-based methodologies for assessing safety could benefit both biopharmas and patients, while helping the U.S. maintain its global position as a clinical research hub...